Literature DB >> 11412835

Regulation of p42/p44 mitogen-activated protein kinase by the human adenosine A3 receptor in transfected CHO cells.

S Graham1, P Combes, M Crumiere, K N Klotz, J M Dickenson.   

Abstract

In this study we have investigated whether the human adenosine A3 receptor activates p42/p44 mitogen-activated protein kinase (MAPK) in transfected Chinese hamster ovary (CHO) cells (designated CHO-A3). The high affinity adenosine A3 receptor agonist IB-MECA (1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-beta-D-ribofuranuronamide) stimulated time (peak activation occurring after 5 min) and concentration-dependent (pEC50=9.0+/-0.2) increases in p42/p44 MAPK in CHO-A3 cells. Adenosine A3 receptor-mediated increases in p42/p44 MAPK were sensitive to pertussis toxin and the MAPK kinase 1 inhibitor PD 98059 (2'-amino-3'-methoxyflavone). The broad range protein tyrosine kinase inhibitor genistein and the phosphatidylinositol 3-kinase inhibitors wortmannin and LY 294002 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) also blocked adenosine A3 receptor stimulation of p42/p44 MAPK. In contrast, inhibition of protein kinase C had no significant effect on adenosine A3 receptor-induced p42/p44 MAPK activation. IB-MECA (pEC50=10.1+/-0.2) also increased the expression of luciferase in CHO-A3 cells transiently transfected with a luciferase reporter gene containing the c-fos promoter. Furthermore, IB-MECA-induced increases in luciferase gene expression were sensitive to pertussis toxin, PD 98059, genistein, wortmannin and LY 294002. In conclusion, we have shown that the human adenosine A3 receptor stimulates p42/p44 MAPK and c-fos-mediated luciferase gene expression in transfected CHO cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11412835     DOI: 10.1016/s0014-2999(01)00976-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  A3 adenosine and CB1 receptors activate a PKC-sensitive Cl- current in human nonpigmented ciliary epithelial cells via a G beta gamma-coupled MAPK signaling pathway.

Authors:  Chanjuan Shi; Anna Szczesniak; Lucy Mao; Christine Jollimore; Miguel Coca-Prados; Orlando Hung; Melanie E M Kelly
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

Review 2.  Adenosine receptors and cancer.

Authors:  P Fishman; S Bar-Yehuda; M Synowitz; J D Powell; K N Klotz; S Gessi; P A Borea
Journal:  Handb Exp Pharmacol       Date:  2009

3.  Characterization of ERK1/2 signalling pathways induced by adenosine receptor subtypes in newborn rat cardiomyocytes.

Authors:  Renée Germack; John M Dickenson
Journal:  Br J Pharmacol       Date:  2004-01       Impact factor: 8.739

4.  Adenosine receptors and second messenger signaling pathways in rat cardiac fibroblasts.

Authors:  Sara A Epperson; Laurence L Brunton; Israel Ramirez-Sanchez; Francisco Villarreal
Journal:  Am J Physiol Cell Physiol       Date:  2009-02-25       Impact factor: 4.249

Review 5.  Immunity, inflammation and cancer: a leading role for adenosine.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Nat Rev Cancer       Date:  2013-11-14       Impact factor: 60.716

6.  An old friend with new skills: Imiquimod as novel inhibitor of Hedgehog signaling in basal cell carcinoma.

Authors:  Wolfgang Gruber; Anna-Maria Frischauf; Fritz Aberger
Journal:  Oncoscience       Date:  2014-09-16

7.  Functional selectivity of adenosine receptor ligands.

Authors:  Dennis Verzijl; Ad P Ijzerman
Journal:  Purinergic Signal       Date:  2011-05-05       Impact factor: 3.765

8.  Mast cell adenosine receptors function: a focus on the a3 adenosine receptor and inflammation.

Authors:  Noam Rudich; Katya Ravid; Ronit Sagi-Eisenberg
Journal:  Front Immunol       Date:  2012-06-04       Impact factor: 7.561

9.  Pharmacological characterisation of novel adenosine A3 receptor antagonists.

Authors:  Kerry Barkan; Panagiotis Lagarias; Margarita Stampelou; Dimitrios Stamatis; Sam Hoare; Dewi Safitri; Karl-Norbert Klotz; Eleni Vrontaki; Antonios Kolocouris; Graham Ladds
Journal:  Sci Rep       Date:  2020-11-27       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.